Thornburg Investment Management Inc. Purchases New Position in Pacira BioSciences, Inc. (NASDAQ:PCRX)

Thornburg Investment Management Inc. purchased a new stake in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 188,590 shares of the company's stock, valued at approximately $5,396,000. Thornburg Investment Management Inc. owned 0.41% of Pacira BioSciences as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of the stock. Vestal Point Capital LP bought a new position in shares of Pacira BioSciences during the fourth quarter valued at approximately $40,488,000. Archon Capital Management LLC bought a new position in Pacira BioSciences in the 1st quarter valued at $15,677,000. Fort Washington Investment Advisors Inc. OH purchased a new stake in Pacira BioSciences in the second quarter worth $13,240,000. Frontier Capital Management Co. LLC lifted its position in shares of Pacira BioSciences by 15.8% during the fourth quarter. Frontier Capital Management Co. LLC now owns 2,084,542 shares of the company's stock worth $70,332,000 after purchasing an additional 285,045 shares during the last quarter. Finally, Norges Bank purchased a new stake in shares of Pacira BioSciences during the fourth quarter valued at $9,542,000. 99.73% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

PCRX has been the topic of several recent analyst reports. Needham & Company LLC reduced their price target on shares of Pacira BioSciences from $43.00 to $22.00 and set a "buy" rating on the stock in a research note on Monday, August 12th. Truist Financial lowered Pacira BioSciences from a "buy" rating to a "sell" rating and lowered their price target for the company from $30.00 to $8.00 in a report on Tuesday, August 13th. StockNews.com lowered Pacira BioSciences from a "strong-buy" rating to a "buy" rating in a research report on Monday, August 12th. JPMorgan Chase & Co. reiterated an "underweight" rating and issued a $10.00 target price (down from $45.00) on shares of Pacira BioSciences in a report on Monday, August 12th. Finally, HC Wainwright cut their price target on Pacira BioSciences from $57.00 to $39.00 and set a "buy" rating on the stock in a research note on Monday, August 12th. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $24.78.

Insider Transactions at Pacira BioSciences

In related news, CEO Frank D. Lee acquired 8,264 shares of the firm's stock in a transaction that occurred on Monday, August 12th. The stock was purchased at an average cost of $12.10 per share, with a total value of $99,994.40. Following the transaction, the chief executive officer now directly owns 107,784 shares of the company's stock, valued at approximately $1,304,186.40. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, insider Jonathan Slonin sold 2,836 shares of Pacira BioSciences stock in a transaction dated Tuesday, July 2nd. The stock was sold at an average price of $28.25, for a total transaction of $80,117.00. Following the completion of the sale, the insider now owns 95,557 shares of the company's stock, valued at $2,699,485.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Frank D. Lee bought 8,264 shares of the company's stock in a transaction that occurred on Monday, August 12th. The stock was purchased at an average price of $12.10 per share, for a total transaction of $99,994.40. Following the transaction, the chief executive officer now owns 107,784 shares of the company's stock, valued at $1,304,186.40. The disclosure for this purchase can be found here. Insiders acquired 11,176 shares of company stock valued at $136,240 in the last quarter. 6.40% of the stock is currently owned by corporate insiders.

Pacira BioSciences Stock Up 3.0 %

Shares of NASDAQ:PCRX traded up $0.38 during trading on Friday, reaching $13.11. The stock had a trading volume of 886,159 shares, compared to its average volume of 878,717. The company has a current ratio of 6.82, a quick ratio of 5.70 and a debt-to-equity ratio of 0.67. The company has a market capitalization of $604.76 million, a P/E ratio of 8.90 and a beta of 0.84. The firm's 50-day simple moving average is $17.31 and its 200 day simple moving average is $24.67. Pacira BioSciences, Inc. has a one year low of $11.16 and a one year high of $35.95.

Pacira BioSciences (NASDAQ:PCRX - Get Free Report) last announced its earnings results on Tuesday, July 30th. The company reported $0.64 earnings per share for the quarter, beating the consensus estimate of $0.53 by $0.11. The company had revenue of $178.02 million during the quarter, compared to the consensus estimate of $173.31 million. Pacira BioSciences had a net margin of 9.21% and a return on equity of 13.22%. As a group, research analysts expect that Pacira BioSciences, Inc. will post 2.24 EPS for the current fiscal year.

Pacira BioSciences Profile

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.